RESUMEN
RESEARCH QUESTION: What is relationship between unexplained recurrent pregnancy loss (RPL) and risk of cancer morbidity? DESIGN: A retrospective observational cohort study was conducted, based on data from a tertiary medical centre. RPL cases (exposed) were defined as women presenting with three or more unexplained confirmed pregnancy losses at 5-24 weeks, whose first visit to the RPL clinic was between 1990 and 2010. The unexposed group included women giving birth who were not RPL patients; these were matched by age and year of giving birth/admission (1:5 ratio). Data from the RPL and the live birth registries were cross-linked to the Israeli national cancer registry according to the unique ID number and merged into one database. RESULTS: The study group comprised 937 RPL patients who were matched by maternal age (Pâ¯=â¯1.0) and admission date (Pâ¯=â¯0.84) to 4685 women achieving a live birth. There was no difference in overall cancer incidence between groups (adjusted odds ratio [OR] 0.76, 95% confidence interval [CI] 0.55-1.03; Pâ¯=â¯0.08). The secondary RPL group showed a trend towards decreased cancer morbidity incidence compared with primary RPL (adjusted OR 0.65, 95% CI 0.41-1.03; Pâ¯=â¯0.07). Analysis by cancer type showed a similar risk for breast cancer among women with RPL compared with live birth, but a significantly lower risk for gynaecological cancers among women with RPL (adjusted OR 0.25, 95% CI 0.08-0.79; Pâ¯=â¯0.018). CONCLUSIONS: Unexplained RPL may be related to a lower risk of gynaecological cancers, possibly explained by hyper-responsive immunological mechanisms involving uterine natural killer cells.
Asunto(s)
Aborto Habitual/inmunología , Neoplasias/epidemiología , Aborto Habitual/patología , Adulto , Estudios de Cohortes , Bases de Datos Factuales , Femenino , Humanos , Incidencia , Edad Materna , Neoplasias/inmunología , Neoplasias/patología , Embarazo , Estudios RetrospectivosRESUMEN
The objective of this systematic review was to assesses whether the orally acting progestagen, dydrogesterone lowers the incidence of subsequent miscarriage in women with recurrent miscarriage. A computerized search was performed in Medline, Embase and Ovid Medline for original reports with the product name "Duphaston" or "dydrogesterone" and limited to clinical human data. Thirteen reports of dydrogesterone treatment were identified. Two randomized trials and one non-randomized comparative trial were identified, including 509 women who fulfilled the criteria for meta-analysis. The number of subsequent miscarriages or continuing pregnancies per woman was compared in women receiving dydrogesterone compared to standard bed rest or placebo intervention. There was a 10.5% (29/275) miscarriage rate after dydrogesterone administration compared to 23.5% in control women (odds ratio for miscarriage 0.29 [confidence interval 0.13-0.65] and 13% absolute reduction in the miscarriage rate). The adverse and side effects were summarised in all 13 reports, and seemed to be minimal. Although all the predictive and confounding factors could not be controlled for, the results of this systematic review show a significant reduction of 29% in the odds for miscarriage when dydrogesterone is compared to standard care indicating a real treatment effect.
Asunto(s)
Aborto Habitual/tratamiento farmacológico , Didrogesterona/uso terapéutico , Progestinas/uso terapéutico , Resultado del Tratamiento , Adulto , Femenino , HumanosRESUMEN
This guideline has been developed based on studied and clinical investigations. Therefore, it appears to be appropriate to use all the available evidence, which are very encouraging, in a summarized form to propose guidelines by a group of European experts in order to give the gynecologists, obstetricians and reproductive medicine specialists have direction with regard to the prevention or treatment of miscarriage for the benefit of the endangered pregnancies. There are a number of statements, opinions and guidelines already published for this topic, which are not entirely in agreement.
Asunto(s)
Aborto Habitual/prevención & control , Amenaza de Aborto/prevención & control , Guías de Práctica Clínica como Asunto/normas , Progestinas/uso terapéutico , Aborto Habitual/tratamiento farmacológico , Amenaza de Aborto/tratamiento farmacológico , Adulto , Europa (Continente) , Femenino , Humanos , Embarazo , Progestinas/administración & dosificación , Sociedades Médicas/normasRESUMEN
The aim of this study was to determine whether women with recurrent pregnancy loss (RPL) and concurrent premenstrual syndrome (PMS) who underwent desensitization with sex hormones had an improved obstetric outcome. This manuscript summarizes a 10 year open label prospective follow up study of 26 women with RPL, aged 25-42 with 3-8 previous miscarriages and PMS, who had hormone hypersensitivity on skin testing. Skin testing was positive to estradiol in 23 women, progesterone in 20 women and to both estrogen and progesterone in 17 women. Amelioration of the symptoms of PMS (according to the VAS) was seen in 21 of 26 patients after desensitization with small doses of sex hormones intradermally. There was long term and stable reduction of severe PMS in 21 of 26 patients after desensitization. Five women conceived after skin testing, prior to desensitization. Sixteen of 26 women (61%) had subsequent live births. Five women had two subsequent live births in the subsequent pregnancy. There were no obstetric complications. Five women had two subsequent pregnancies with live births. It seems that correction of sex hormone hypersensitivity was accompanied by relief of persistent PMS, may have a positive effect on the chances of a successful pregnancy.
Asunto(s)
Aborto Habitual/prevención & control , Desensibilización Inmunológica , Pérdida del Embrión/prevención & control , Estradiol/análogos & derivados , Síndrome Premenstrual/terapia , Progesterona/administración & dosificación , Aborto Habitual/etiología , Adulto , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/fisiopatología , Enfermedades Autoinmunes/terapia , Estudios de Cohortes , Pérdida del Embrión/etiología , Estradiol/administración & dosificación , Estradiol/efectos adversos , Estrógenos/administración & dosificación , Estrógenos/efectos adversos , Femenino , Humanos , Inyecciones Intradérmicas , Nacimiento Vivo , Estudios Longitudinales , Embarazo , Síndrome Premenstrual/inmunología , Síndrome Premenstrual/fisiopatología , Progesterona/efectos adversos , Estudios Prospectivos , Prevención Secundaria , Índice de Severidad de la EnfermedadRESUMEN
Several lines of evidence suggest that autoimmune mechanisms may influence the reproductive life and fertility of both sexes, commonly manifesting as infertility or pregnancy loss. Part of the controversy that characterizes this assumption derives from the overlooked suspect of autoimmune conditions in the absence of symptoms or the limited physician awareness in a gynecological setting. Numerous autoimmune diseases, including but not limited to systemic lupus erythematosus and anti-phospholipid syndrome, may be associated with infertility and pregnancy loss through different putative mechanisms. First, serum autoantibodies such as anti-phospholipid, anti-thyroid, or antinuclear antibodies may be directly associated with infertility, regardless of the presence of a clinically overt autoimmune disease. Second, autoimmunity may affect all stages of fertility, via ovarian failure, testicular failure, implantation failure, and pregnancy loss. Third, infertility may also be secondary to vasculitis associated with other conditions such as systemic lupus erythematosus and diabetes mellitus. This review article will illustrate and critically discuss the available data on the link between the breakdown of tolerance that characterizes autoimmune diseases and the changes in reproductive life that affect patients in real clinical setting and that often constitute the iatrotropic stimulus.
Asunto(s)
Aborto Espontáneo/inmunología , Autoinmunidad , Infertilidad/inmunología , Aborto Espontáneo/etiología , Aborto Espontáneo/genética , Autoanticuerpos/inmunología , Enfermedades Autoinmunes/complicaciones , Enfermedades Autoinmunes/inmunología , Autoinmunidad/genética , Cromosomas Humanos X , Endometriosis/inmunología , Endometrio/inmunología , Femenino , Humanos , Inmunomodulación , Infertilidad/etiología , Infertilidad/genética , Masculino , Embarazo , Insuficiencia Ovárica Primaria/inmunología , Enfermedades Testiculares/inmunología , Trofoblastos/inmunologíaRESUMEN
The objective of this systematic review was to assess whether the orally acting progestagen, dydrogesterone lowers the incidence of miscarriage in women with threatened miscarriage. A computerized search was performed in Medline, Embase, and Ovid Medline for original reports with the product name 'Duphaston' or 'dydrogesterone', and limited to clinical human data. Twenty-one reports of dydrogesterone treatment were identified with 1380 patients. Five randomized trials were identified, including 660 women who fulfilled the criteria for meta-analysis. The number of subsequent miscarriages or continuing pregnancies per randomized woman was compared in women receiving dydrogesterone compared to standard bed rest or placebo intervention. There was a 13% (44/335) miscarriage rate after dydrogesterone administration compared to 24% in control women [odds ratio for miscarriage 0.47, (CI = 0.31-0.7), 11% absolute reduction in the miscarriage rate]. The adverse and side effects were summarized in all 21 reports, and seemed to be minimal. Although all the predictive and confounding factors could not be controlled for, the results of this systematic review show a significant reduction of 47% in the odds for miscarriage when dydrogesterone is compared to standard care indicating a real treatment effect.
Asunto(s)
Aborto Espontáneo/prevención & control , Amenaza de Aborto/tratamiento farmacológico , Didrogesterona/uso terapéutico , Progestinas/uso terapéutico , Administración Oral , Didrogesterona/administración & dosificación , Didrogesterona/efectos adversos , Medicina Basada en la Evidencia , Femenino , Estudios de Seguimiento , Humanos , Embarazo , Progestinas/administración & dosificación , Progestinas/efectos adversos , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
Patients with five or more unexplained recurrent pregnancy losses (RPL) have a poor prognosis for a subsequent delivery compared to patients with two to three RPL. Treatment guidelines are needed to address this select group of patients.
Asunto(s)
Aborto Habitual/etiología , Pérdida del Embrión/etiología , Medicina de Precisión , Aborto Habitual/diagnóstico , Aborto Habitual/prevención & control , Anomalías Congénitas/embriología , Anomalías Congénitas/fisiopatología , Pérdida del Embrión/diagnóstico , Pérdida del Embrión/prevención & control , Medicina Basada en la Evidencia , Femenino , Enfermedades Fetales/fisiopatología , Enfermedades Fetales/prevención & control , Enfermedades Genéticas Congénitas/embriología , Enfermedades Genéticas Congénitas/fisiopatología , Humanos , Guías de Práctica Clínica como Asunto , Embarazo , Complicaciones del Embarazo/fisiopatología , Complicaciones del Embarazo/prevención & control , Pronóstico , Prevención SecundariaRESUMEN
STUDY OBJECTIVE: To evaluate the clinical and surgical features of thoracic endometriosis syndrome (TES) represented by catamenial pneumothorax and pelvic endometriosis and to describe their association with infertility. DESIGN: Retrospective clinical study (Canadian Task Force classification: II-2). SETTING: Academic tertiary referral endometriosis center. PATIENTS: Seven patients who had undergone surgery because of thoracic and pelvic endometriosis between 2004 and 2010. INTERVENTIONS: Thoracic and pelvic exploration and treatment and fertility treatment. MEASUREMENTS AND MAIN RESULTS: Concurrently, thoracic and pelvic endometriosis, and subsequent fertility were determined during long-term follow-up after combined surgical and pharmacologic interventions. The most frequent thoracic finding was diaphragmatic implants. Except for 1 patient with recurrent pleurodesis at 1 month after video-assisted thoracoscopy, no patients experienced recurrence of thoracic symptoms during a median (range) follow-up of 31.4 (1-61) months. Severe pelvic endometriosis was diagnosed in 6 patients with notable urologic and gastrointestinal tract involvement. Only 1 patient with catamenial pneumothorax had no macroscopic pelvic lesions. There was a considerable delay between the onset of pelvic symptoms and diagnosis. Median postoperative follow-up was 31.5 (7-84) months. Most patients who tried to conceive had primary infertility. CONCLUSION: Thoracic endometriosis syndrome, represented by catamenial pneumothorax, was strongly associated with severe pelvic endometriosis and a high rate of infertility. Inasmuch as many patients with thoracic endometriosis syndrome are treated by thoracic surgeons using video-assisted thoracoscopy, it is desirable to involve an experienced gynecologist who can diagnose and treat concurrent pelvic endometriosis.
Asunto(s)
Endometriosis/complicaciones , Enfermedades Urogenitales Femeninas/complicaciones , Enfermedades Pulmonares/complicaciones , Enfermedades Pleurales/complicaciones , Adolescente , Adulto , Diafragma , Dismenorrea/tratamiento farmacológico , Dismenorrea/etiología , Endometriosis/terapia , Femenino , Enfermedades Urogenitales Femeninas/diagnóstico , Enfermedades Urogenitales Femeninas/terapia , Hormona Liberadora de Gonadotropina/uso terapéutico , Humanos , Infertilidad Femenina/complicaciones , Enfermedades Pulmonares/terapia , Enfermedades Pleurales/terapia , Pleurodesia , Neumonectomía , Neumotórax/etiología , Neumotórax/cirugía , Estudios Retrospectivos , Cirugía Torácica Asistida por Video , Adulto JovenRESUMEN
OBJECTIVE: To describe the characteristics and peripartum outcomes of patients diagnosed with uterine rupture (UR) by an observational cohort retrospective study on 270 patients. METHODS: Demographic information, surgical history, symptoms, and postoperative outcome of women and neonates after UR were collected in a large database. The statistical analysis searched for correlation between UR, previous uterine interventions, fibroids, and the successive perinatal outcomes in women with previous UR. RESULTS: Uterine rupture was significantly associated with previous uterine surgery, occurring, on average, at 36 weeks of pregnancy in women also without previous uterine surgery. UR did not rise exponentially with an increasing number of uterine operations. Fibroids were related to UR. The earliest UR occurred at 159 days after hysteroscopic myomectomy, followed by laparoscopic myomectomy (251 days) and laparotomic myomectomy (253 days). Fertility preservation was feasible in several women. Gestational age and birth weight seemed not to be affected in the subsequent pregnancy. CONCLUSION: Data analysis showed that previous laparoscopic and abdominal myomectomies were associated with UR in pregnancy, and hysteroscopic myomectomy was associated at earlier gestational ages. UR did not increase exponentially with an increasing number of previous scars. UR should not be considered a contraindication to future pregnancies.
Asunto(s)
Leiomioma , Miomectomía Uterina , Neoplasias Uterinas , Rotura Uterina , Femenino , Humanos , Recién Nacido , Leiomioma/cirugía , Embarazo , Estudios Retrospectivos , Neoplasias Uterinas/cirugía , Rotura Uterina/epidemiología , Rotura Uterina/etiología , Rotura Uterina/cirugíaRESUMEN
Despite evidence for the important role of oestrogens in the aetiology and pathophysiology of chronic immune/inflammatory diseases, the previous view of an unequivocal beneficial effect of oestrogens on RA compared with a detrimental effect on SLE has to be reconsidered. Likewise, the long-held belief that RA remits in the majority of pregnant patients has been challenged, and shows that only half of the patients experience significant improvement when objective disease activity measurements are applied. Pregnancies in patients with SLE are mostly successful when well planned and monitored interdisciplinarily, whereas a small proportion of women with APS still have adverse pregnancy outcomes in spite of the standard treatment. New prospective studies indicate better outcomes for pregnancies in women with rare diseases such as SSc and vasculitis. Fertility problems are not uncommon in patients with rheumatic disease and need to be considered in both genders. Necessary therapy, shortly before or during the pregnancy, demands taking into account the health of both mother and fetus. Long-term effects of drugs on offspring exposed in utero or during lactation is a new area under study as well as late effects of maternal rheumatic disease on children.
Asunto(s)
Enfermedades Autoinmunes/fisiopatología , Embarazo/fisiología , Reproducción/fisiología , Enfermedades Reumáticas/fisiopatología , Femenino , Hormonas Esteroides Gonadales/fisiología , Humanos , Complicaciones del Embarazo/fisiopatología , Resultado del EmbarazoRESUMEN
Progestational agents are often prescribed to increase the clinical pregnancy rate in assisted reproduction. Progestogens affect implantation, cytokine balance, natural killer cell activity, arachidonic acid release and myometrial contractility. Progesterone production from the corpus luteum is essential for reproduction, but assisted reproductive technologies (ART) can impair luteal function. ART cycles can be classified into three, fresh cycles in which there may or may not be luteal insufficiency, agonist or antagonist cycles in which there is luteal insufficiency, and luteal support is essential, and donor cycles, in which there is no corpus luteum, and a luteal phase has to be created. However, there is no adequate diagnostic test for luteal insufficiency. This article summarises the effect of various progestogens, progesterone itself whether administered vaginally, intra-muscularly, rectally or subcutaneously, and the effect of the progestogen, dydrogesterone. The time of commencement and cessation of therapy are also discussed. Progestogens are also often used to treat threatened and recurrent miscarriage. In these patients progestogen supplementation may need to be prolonged. In threatened miscarriage, until after all bleeding stops, and in recurrent miscarriage, at least as long as the luteo-placental shift.
Asunto(s)
Fase Luteínica/efectos de los fármacos , Progestinas/farmacología , Progestinas/uso terapéutico , Toma de Decisiones Clínicas , Ensayos Clínicos como Asunto , Manejo de la Enfermedad , Endometrio/efectos de los fármacos , Endometrio/fisiología , Femenino , Fertilización In Vitro , Humanos , Embarazo , Progesterona/farmacología , Progesterona/uso terapéutico , Técnicas Reproductivas Asistidas , Resultado del TratamientoRESUMEN
Mammalian olfaction and reproduction are tightly linked, a link less explored in humans. Here, we asked whether human unexplained repeated pregnancy loss (uRPL) is associated with altered olfaction, and particularly altered olfactory responses to body-odor. We found that whereas most women with uRPL could identify the body-odor of their spouse, most control women could not. Moreover, women with uRPL rated the perceptual attributes of men's body-odor differently from controls. These pronounced differences were accompanied by an only modest albeit significant advantage in ordinary, non-body-odor-related olfaction in uRPL. Next, using structural and functional brain imaging, we found that in comparison to controls, most women with uRPL had smaller olfactory bulbs, yet increased hypothalamic response in association with men's body-odor. These findings combine to suggest altered olfactory perceptual and brain responses in women experiencing uRPL, particularly in relation to men's body-odor. Whether this link has any causal aspects to it remains to be explored.
Asunto(s)
Aborto Habitual/fisiopatología , Hipotálamo , Trastornos del Olfato , Bulbo Olfatorio , Olfato/fisiología , Adulto , Femenino , Humanos , Hipotálamo/anatomía & histología , Hipotálamo/diagnóstico por imagen , Hipotálamo/metabolismo , Masculino , Odorantes/análisis , Trastornos del Olfato/diagnóstico por imagen , Trastornos del Olfato/fisiopatología , Bulbo Olfatorio/anatomía & histología , Bulbo Olfatorio/diagnóstico por imagen , Bulbo Olfatorio/metabolismo , Corteza Prefrontal/anatomía & histología , Corteza Prefrontal/diagnóstico por imagen , EmbarazoRESUMEN
When immunomodulation is used on an unselected population with recurrent miscarriage (RM), there is no improvement in the live birth rate. However, when the population is selected for a poor prognosis, or immune phenomena, immunotherapy has been shown to be effective. This review discusses four immunomodulatory agents, namely, paternal leukocyte immunization, intravenous immunoglobulin (IVIg), intralipid, and filgrastim. The presence of embryonic aneuploidy may confound the results of treatment, therefore creating an impression of futility when treatment may be highly effective in saving pregnancies that can be saved. Additionally, in an unselected population with RM, there is a relatively good prognosis of 60-80% for a subsequent live birth depending on whether the definition of ≥2 or ≥3 miscarriages is used. Hence, spontaneous prognosis must be taken into account, which has not been the case in previous trials. This review discusses the possible immune-mediated mechanisms of pregnancy loss and the means whereby immunotherapy may modulate these mechanisms.
Asunto(s)
Aborto Habitual , Inmunoterapia , Aborto Habitual/inmunología , Aborto Habitual/terapia , Femenino , Humanos , Nacimiento Vivo , Embarazo , Pronóstico , VacunaciónRESUMEN
STUDY OBJECTIVE: Bladder involvement is rare in endometriosis. The prevalence is estimated to be â¼1% in patients with endometriosis. However, this figure seems to be an underestimation. The diagnosis of bladder endometriosis might be missed during laparoscopy. The aim of this study was to determine an intraoperative visual score of pelvic lesions that help the surgeon suspect bladder endometriosis. Design, Design Classification: A retrospective analysis was performed on the intraoperative photographs and videos of 69 patients with histological confirmation of bladder endometriosis. SETTING: A tertiary referral center. PATIENTS: Sixty-nine patients with bladder endometriosis were operated on in our center over a 9-year period. INTERVENTIONS: Evaluation and analysis of intraoperative laparoscopic findings. MAIN RESULTS: We found three subtypes of laparoscopic findings that can assist with diagnosing bladder endometriosis. The most prominent sign was named "kissing round ligaments" (Type K), in which the right and left round ligaments appear closer to each other than usual or even touching one another. This sign is strongly associated with full-thickness invasion of the bladder. Other laparoscopic findings that indicated bladder endometriosis were anatomical distortion (Type A) and proximal occlusion of the tubes (Type B). We further define a scoring system for the lesion that correlates with the severity of the bladder endometriosis from superficial lesions to full thickness. CONCLUSION: Bladder endometriosis is a rare condition and often remains undiagnosed. Indeed, even during surgery, bladder endometriosis can be missed if the operator is not aware of the suggestive signs. Operative laparoscopic findings may help the surgeon to diagnose bladder endometriosis, and these signs correlate with the severity of the disease.
Asunto(s)
Endometriosis/cirugía , Laparoscopía/métodos , Enfermedades de la Vejiga Urinaria/cirugía , Vejiga Urinaria/patología , Adulto , Endometriosis/diagnóstico , Femenino , Humanos , Persona de Mediana Edad , Estudios Retrospectivos , Centros de Atención Terciaria , Vejiga Urinaria/cirugía , Enfermedades de la Vejiga Urinaria/diagnósticoRESUMEN
Many unanswered questions regarding thrombophilia and recurrent pregnancy loss exist. For example, does a true association exist? Are thrombotic mechanisms relevant? Is a second messenger necessary to cause the manifestation of thrombosis? At present it seems that thrombophilia are associated with and may even cause some cases of pregnancy loss. The role of treatment remains to be determined. Although the aim of physicians working in this field is entirely laudable, to allow childless couples to have children, it is necessary to have good evidence of effect before treatment is given to all patients. A serious ethical dilemma remains, however, namely should treatment that may be effective be denied to patients who have prior pregnancy losses? Denial of treatment is extremely distressing for the patient and the physician. The author's own practice is to offer treatment after a full explanation, particularly because treatment is generally prescribed in the antiphospholipid syndrome and justified in hereditary thrombophilias according to the report of Carp and colleagues, showing a 25% improvement in live birth rates in treated patients. When treatment fails, however, the embryo should be karyotyped to exclude chromosomal aberrations.
Asunto(s)
Aborto Habitual/etiología , Trombofilia/complicaciones , Aborto Habitual/epidemiología , Aborto Habitual/patología , Aborto Habitual/prevención & control , Anticoagulantes/uso terapéutico , Apoptosis , Femenino , Fibrinolíticos/uso terapéutico , Hormonas , Humanos , Placenta/patología , Embarazo , Pronóstico , Trombofilia/tratamiento farmacológicoRESUMEN
Progestational agents are often prescribed to prevent threatened miscarriage progressing to miscarriage, and subsequent miscarriages in recurrent pregnancy loss. Progestogens affect implantation, cytokine balance, natural killer cell activity, arachidonic acid release and myometrial contractility. A recent Cochrane review reported that progestogens were effective for treating threatened miscarriage with no harmful effects on mother or fetus. The results were not statistically different when vaginal progesterone was compared to placebo, (RR=0.47, 95% CI 0.17-1.30), whereas oral progestogen (dydrogesterone) was effective (RR=0.54, CI 0.35-0.84). The review concluded, that the small number of eligible studies, and the small number of the participants, limited the power of the metaanalysis. A later metaanalysis of five randomised controlled trials of threatened miscarriage comprised 660 patients. The results of 335 women who received dydrogesterone were compared to 325 women receiveing either placebo or bed rest. There was a 47% reduction in the odds ratio for miscarriage, (OR=0.47, CI 0.31-0.7). There was a 13% (44/335) miscarriage rate after dydrogesterone administration compared to 24% in control women. Recurrent miscarriage affects approximately 1% of women of child bearing age. A metaanalysis of progestational agents shows a 26% increase in the live birth rate. Again, dydrogesterone was associated with a more significant increase in the live birth rate than the other progestogens included in the metaanalysis.
Asunto(s)
Aborto Espontáneo/prevención & control , Progestinas/uso terapéutico , Aborto Espontáneo/tratamiento farmacológico , Aborto Espontáneo/etiología , Ensayos Clínicos como Asunto , Femenino , Humanos , Embarazo , Progestinas/administración & dosificación , Progestinas/efectos adversosRESUMEN
Intravenous immunoglobulin (IVIg) has been used to prevent pregnancy loss, in unexplained recurrent miscarriage, and in antiphospholipid syndrome (APS). When used on an unselected population with recurrent miscarriage, IVIg has not been shown to improve the live birth rate. However, when patients are selected for poor prognosis or autoimmune phenomena, IVIg has been shown to be effective. This article discusses the possible immune mechanisms by which IVIg may act and the effect of confounding factors such as embryonic chromosomal aberrations or anti-beta2-glycoprotein I antibodies in APS. Hence, there may be an impression of futility, when IVIg may be highly effective in saving those pregnancies that can be saved. Additionally, in an unselected population with recurrent miscarriage, there is a relatively good prognosis for a subsequent live birth (60%). Therefore, the spontaneous prognosis must be taken into account, which has not been the case in previous trials.
Asunto(s)
Aborto Habitual/tratamiento farmacológico , Síndrome Antifosfolípido/tratamiento farmacológico , Inmunoglobulinas Intravenosas/uso terapéutico , Aborto Habitual/etiología , Animales , Síndrome Antifosfolípido/complicaciones , Femenino , Humanos , EmbarazoRESUMEN
Miscarriages are the most common complication in human pregnancies. Recurrent pregnancy loss (RPL) could occur for several reasons, such as: immunological abnormalities of the pregnant women and chromosomal abnormalities of the embryo. There are several autoimmune characteristics for RPL, such as autoantibodies, and sometimes RPL are a symptom of an autoimmune disease. It is unclear whether the autoantibodies are the cause, the consequence or an artifact of the RPL. Intravenous immunoglobulin (IVIG) is a preparation made of purified plasma of thousands of healthy donors. Currently, IVIG is provided as a treatment for several autoimmune diseases. There are reports on a beneficial effect of IVIG for women with RPL of unknown reason. Some reports indicate a beneficial effect of IVIG independent of aspirin, as well as in artificial fertilization. Nevertheless, the efficacy of IVIG has yet to be established. Perhaps a certain sub-group should be defined of women who suffer from RPL and have greater odds for successful IVIG treatment. A sub-group analysis showed that, in secondary RPL, IVIG is more successful when provided after embryo implantation, whereas, in primary RPL, IVIG is better when provided prior to conceiving. Apart from the miscarriage type (secondary or primary) other factors that might influence the IVIG-treatment success were found: the number of previous miscarriages, the age of the pregnant women and the way IVIG is administrated. The mechanisms of action of IVIG in RPL are multiple, complex and not fully understood. IVIG therapy regulates the immune system in several mechanisms, in a way that might increase the survival rate of the embryo in the uterus and might decrease the odds of a miscarriage. For example, one of the main mechanisms of IVIG in RPL is down-regulation of natural killer cells (NK cells) activity and expression. This finding is of great importance because it has been reported that women who have never given birth and have high levels of NK cells in their peripheral blood have higher chances of pregnancy loss. In conclusion, IVIG is an immunomodulator that exerts its beneficial effects in multiple mechanistic ways acting together synergistically. IVIG is a potential treatment for women with RPL as a result of immunological abnormalities.